Alx Oncology Holdings (ALXO) Research & Development (2019 - 2026)
Alx Oncology Holdings (ALXO) posted Research & Development of $13.6 million for Q1 2026, down 22.89% sequentially from $17.6 million in Q4 2025, and down 43.04% YoY from $23.9 million in Q1 2025.
Alx Oncology Holdings (ALXO) Research & Development (2019 - 2026) Analysis & Trends
Alx Oncology Holdings has reported Research & Development for 8 years, with the latest figure at $13.6 million in Q1 2026.
- Quarterly Research & Development fell 43.04% year-over-year to $13.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.7 million (down 38.54% YoY) and the FY2025 annual result came in at $77.0 million, down 33.84% from the prior year.
- Research & Development declined to $13.6 million in Q1 2026 per ALXO's latest filing, from $17.6 million in the prior quarter.
- Over five years, Research & Development peaked at $45.8 million in Q3 2023 and troughed at $13.6 million in Q1 2026.
- A 5-year average of $26.3 million and a median of $25.2 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development jumped 138.54% in 2022, then slumped 47.99% in 2025.
- Over 5 years, Research & Development stood at $25.2 million in 2022, then surged by 65.83% to $41.8 million in 2023, then slumped by 43.68% to $23.5 million in 2024, then fell by 25.02% to $17.6 million in 2025, then fell by 22.89% to $13.6 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $13.6 million, $17.6 million, and $17.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Alx Oncology Holdings | 270.90 Mn | 270.90 Mn | - | 13.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.14 Mn |
| Mar 31, 2026 | 13.61 Mn |
| Dec 31, 2025 | 17.65 Mn |
| Sep 30, 2025 | 17.44 Mn |
| Jun 30, 2025 | 18.02 Mn |
| Mar 31, 2025 | 23.89 Mn |
| Dec 31, 2024 | 23.53 Mn |
| Sep 30, 2024 | 26.47 Mn |
| Jun 30, 2024 | 34.65 Mn |
| Mar 31, 2024 | 31.72 Mn |
| Dec 31, 2023 | 41.78 Mn |
| Sep 30, 2023 | 45.77 Mn |
| Jun 30, 2023 | 29.48 Mn |
| Mar 31, 2023 | 24.76 Mn |
| Dec 31, 2022 | 25.20 Mn |
| Sep 30, 2022 | 29.38 Mn |
| Jun 30, 2022 | 26.75 Mn |
| Mar 31, 2022 | 17.07 Mn |
| Dec 31, 2021 | 20.89 Mn |
| Sep 30, 2021 | 18.21 Mn |